VISIBLE ALPHA AUTHOR:

About

Rahul is Head of BioPharma Research at Visible Alpha. He has more than 20 years of experience in the biopharmaceutical drug development field encompassing the capital markets, equity research, technology and competitive due diligence, investor outreach, licensing and intellectual property management, business development, and corporate/board leadership. Rahul conducted doctoral and post-doctoral research at Harvard Medical School, in the Department of Hematology and Oncology at Beth Israel Deaconess Medical Center. He received his Ph.D. in Immunology from Tufts University School of Medicine in Boston, M.S. in Microbiology from the University of Montana, Missoula, and B.Sc. in Microbiology from the University of Bombay.

Articles by Rahul:

Eli Lilly’s Donanemab Treatment for Alzheimer’s Faces Regulatory Approval Delays
June 18, 2024

Eli Lilly’s Donanemab Gets Positive FDA Advisory Committee Review

Merck’s Drug Candidate Could Change the Hypercholesterolemia Landscape
June 6, 2024

Merck’s Oral Drug Candidate Could Change the Hypercholesterolemia Landscape

Viking Therapeutics’ New Weight Loss Drug Shows Promise in Phase 2a Obesity Study
May 30, 2024

Viking Therapeutics’ Weight-Loss Drug Shows Promise in Phase 2a Obesity Study

Major Clinical Data Unveiled for Novo Nordisk (NVO) Obesity Drug Wegovy
May 16, 2024

Major Clinical Data Unveiled for Novo Nordisk (NVO) Obesity Drug Wegovy

Visible Alpha GLP 1 Drug Monitor
March 26, 2024

Visible Alpha GLP-1 Drug Monitor: Blockbusters & Up-and-Comers

Madrigal Pharma s Resmetirom Approaching FDA Review for NASH
February 12, 2024

Madrigal Pharma’s Resmetirom Approaching FDA Review for NASH

FDA Approvals A Look Ahead in 2024
January 31, 2024

Potential FDA Approvals: A Look Ahead for 2024

Emerging Drugs Show Promise in Targeting Difficult to Treat Cancers
November 1, 2023

Emerging Drugs Show Promise in Targeting Difficult-to-Treat Cancers

Soaring Revenue Projections for Eli Lilly’s Mounjaro
October 12, 2023

Soaring Revenue Projections for Eli Lilly’s Mounjaro (Diabetes & Obesity)

Eli Lilly Plans to Acquire DICE Therapeutics for $2.4B
June 28, 2023

Eli Lilly Plans to Acquire DICE Therapeutics for $2.4B

Roche’s Vabysmo to Challenge Eylea’s Dominance for Wet AMD
May 25, 2023

Roche’s Vabysmo to Challenge Eylea’s Dominance in Wet AMD Treatment